Robert Vanhimbergen Acquires 6,950 Shares of Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health Incorporated (NYSE:ELAN) CFO Robert Vanhimbergen acquired 6,950 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The stock was acquired at an average cost of $21.64 per share, with a total value of $150,398.00. Following the completion of the transaction, the chief financial officer directly owned 124,233 shares of the company’s stock, valued at $2,688,402.12. This trade represents a 5.93% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Elanco Animal Health Trading Up 3.6%

Shares of ELAN stock opened at $22.49 on Wednesday. The firm has a market capitalization of $11.17 billion, a P/E ratio of 374.81, a price-to-earnings-growth ratio of 2.95 and a beta of 1.86. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $23.70. The firm’s fifty day simple moving average is $21.79 and its 200 day simple moving average is $18.22. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the firm earned $0.13 EPS. The business’s revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ELAN shares. Barclays started coverage on Elanco Animal Health in a research note on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target on the stock. Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Wednesday, November 19th. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $18.00 to $24.00 in a research report on Tuesday, October 7th. UBS Group boosted their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Stifel Nicolaus increased their price objective on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $22.78.

Institutional Trading of Elanco Animal Health

A number of large investors have recently bought and sold shares of the stock. Primecap Management Co. CA boosted its stake in shares of Elanco Animal Health by 3.1% in the 2nd quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after purchasing an additional 1,543,279 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Elanco Animal Health by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock valued at $978,536,000 after purchasing an additional 759,623 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Elanco Animal Health by 8.6% in the third quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock valued at $497,610,000 after buying an additional 1,962,276 shares in the last quarter. UBS Group AG grew its stake in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after buying an additional 5,961,457 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its stake in Elanco Animal Health by 1.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company’s stock worth $167,826,000 after buying an additional 292,655 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.